StockData

Aardvark Therapeutics vs vTv Therapeutics

AARD and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AARD and VTVT compare

vTv Therapeutics is the larger company, worth 2.7 times as much as Aardvark Therapeutics ($68.4M against $25.2M).

vTv Therapeutics scores higher on the StockData Score (11 against 6 for Aardvark Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAARDVTVT
Size and price
Market cap$25.2M$68.4M
Share price$1.15$17.29
Change, 1 year−88.4%−43.9%
Change, 5 years–−67.7%
Beta (5Y)5.010.08
Employees4026
StockData Score
Total score611 (better)
Valuation score13 (better)
Growth score01 (better)
Performance score02 (better)
Health score55
Dividend score00
Valuation
P/S–1.9×
P/B0.3× (better)0.9×
Fair value–$44.97
Margin of safety–61.6%
Growth
Revenue growth (TTM)–216600%
Profitability
Operating margin–−25.1%
Net margin–−12.9%
Return on equity−66.0%−11.7% (better)
Financial health
Debt / equity0.000.00
Current ratio12.63 (better)12.48
Altman Z-score−2.250.71 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions43.6%40.6%
Held by insiders41.9%26.3%
Insider net buying, 12 months−$250K–
Short interest, % of float8.2%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.